163MO Randomized phase II study of eribulin-based neoadjuvant chemotherapy for triple-negative primary breast cancer patients stratified by homologous recombination deficiency status (JBCRG-22).

Autor:	Bando, H.1 (AUTHOR), Masuda, N.2 (AUTHOR), Yamanaka, T.3 (AUTHOR), Kadoya, T.4 (AUTHOR), Takahashi, M.5 (AUTHOR), Nagai, S.6 (AUTHOR), Ohtani, S.7 (AUTHOR), Aruga, T.8 (AUTHOR), Suzuki, E.9 (AUTHOR), Kikawa, Y.10 (AUTHOR), Yasojima, H.2 (AUTHOR), Kasai, H.11 (AUTHOR), Ishiguro, H.12 (AUTHOR), Kawabata, H.13 (AUTHOR), Morita, S.14 (AUTHOR), Haga, H.15 (AUTHOR), Kataoka, T.R.15 (AUTHOR), Uozumi, R.14 (AUTHOR), Ohno, S.16 (AUTHOR), Toi, M.17 (AUTHOR)
Zdroj:	Annals of Oncology. 2020 Supplement 4, Vol. 31, pS305-S306. 2p.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu